|
Today's Headlines
Women who take HRT for 10 years following menopause have a significantly reduced risk of mortality, heart failure, and heart attack without any increased risk of cancer, DVT, or stroke, a Danish study published on bmj.com showed. » Full article
|
|
With medication misuse resulting in more than 1 million adverse drug events per year in the United States, new standards released today by the U.S. Pharmacopeial Convention for the first time, provide a universal approach to the format, appearance, content, and language of instructions for medicines in containers dispensed by pharmacists. » Full article
|
|
New evidence suggests that statins generate large survival and health benefits at the population level and shows that the social value of the survival gains are large and go predominantly to consumers, according to a study published in the October issue of Health Affairs. » Full article
|
|
Screening patients who are at high risk for diabetes does not reduce their all-cause, cardiovascular, or diabetes-related mortality within 10 years, according to a study published October 4 in The Lancet. » Full article
|
|
CONTINUING EDUCATION
Welcome to the second activity of our new CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 CPE credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The October activity will cover medical nutrition therapy, physical activity, and health maintenance considerations for patients with diabetes. To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.
Coming soon - All users will be required to provide their NABP e-Profile ID when logging into the Drug Topics' FREE CPE. This new process requires all pharmacists and pharmacy technicians to provide their NABP e-Profile ID prior to accessing the system. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.
|
|
EDITOR'S PICK
Rheumatoid arthritis (RA) is a chronic, inflammatory disease characterized by synovial inflammation and destruction of joint cartilage, which afflicts mainly the elderly and women of northern Europe and North America. Disease-modifying antirheumatic drugs (DMARDs), which are further subdivided into nonbiologic and biologic types, are the mainstay of RA therapy. A new drug application for tofacitinib, an orally administered Janus kinase inhibitor for treatment of RA, was submitted to FDA with anticipated action date in November 2012. In clinical studies, tofacitinib was administered twice daily, had rapid absorption, and required dosage adjustments for patients with renal or hepatic impairment and for those taking concomitant potent inhibitors of CYP3A4. » Full article
|
Survey
a) Hardly ever
b) Once a week
c) Once a month
d) Once a day
Respond here and see what your colleagues think too.Want to see the results of our last survey. Click here.
|
|
|
Like
Tweet
